pseudoephedrine/loratadine (Alavert Allergy and Sinus D, Claritin D, ChlorTripolon, Alavert D-12, Claritin D-24 Hour)

Dosing and uses of Alavert Allergy and Sinus D, Claritin D (pseudoephedrine/loratadine)

• Adult
• Pediatric

 

Adult dosage forms and strengths

pseudoephedrine/loratadine

tablet, extended release

• 5mg/120mg
• 10mg/240mg

 

Allergic Rhinitis/Nasal Congestion

Immediate release: 1 tablet PO q12hr

Extended release: 1 tablet PO qd

 

Administration

Tablet should be swallowed whole & not broken, dissolved or chewed

Claritin-D extended release to be taken with a full glass of water

 

Other Indications & Uses

Perennial & seasonal allergic & vasomotor rhinitis, relief of symptoms from colds, urticaria, angioedema, anaphylactic reactions, pruritus, allergic conjunctivitis

 

Pediatric dosage forms and strengths

pseudoephedrine/loratadine

tablet, extended release

• 5mg/120mg
• 10mg/240mg

 

Allergic Rhinitis/Nasal Congestion

<12 years old

• Safety & efficacy not established

>12 years old

• Immediate release: 1 tablet PO q12hr
• Extended release: 1 tablet PO qD

 

Warnings

Contraindications

Documented hypersensitivity

Lower respiratory disease, eg, asthma (controversial)

Preemies & neonates

Nursing women

Concurrent or within 2 wk of MAO inhibitor use

Hepatic impairment

 

Cautions

Renal impairment, heart disease, BPH, hypertension, diabetes, glaucoma

Pregnancy/lactation

 

Pregnancy and lactation

Pregnancy category: B

Lactation: both drugs pass into breast milk, pseuoephedrine is concentrated in breast milk; use caution

 

Pregnancy categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.